Intentar ORO - Gratis
APAC's 5G ambitions in Healthcare
BioSpectrum Asia
|November 2020
The surge in virtual healthcare has prompted physicians globally to engage in co-sharing their medical space and expertise. And Internet-of-Things (IoT) is driving next-generation smart healthcare. Boosted by advances in robotics, IoT and Artificial Intelligence, healthcare organisations across the globe have started using 5G network that promises to provide essential levels of connectivity to enable a new health ecosystem, which will align with a relatively recent idea known as 4P medicine—that is, it will be predictive, preventative, personalised and participatory, as noted by PwC.
At present, most countries’ healthcare system widely uses the existing 4G (fourth generation of broadband cellular network technology) network and other communication technologies for smart healthcare applications. The existing communication technologies are unable to fulfil the complex and dynamic needs of the diverse smart healthcare applications, such as remote surgeries which imperatively require an ultrareliable network.
4G latency (lag time between input and output) is around 50 milliseconds, a delay long enough to prove devastating in an operating room. 5G (fifth generation mobile network) primarily aims to reduce latency to an almost instantaneous 2 milliseconds between devices. Hence a 5G network is essential to support smart healthcare infrastructure, through its ultra-low latency, high bandwidth, ultra-high reliability, high density and energy efficiency.
The ultra-reliable low-latency communications (URLLC) is advantageous for remote monitoring of pharma and medical devices, remote robotic surgeries, smart ambulance (logistics), and realtime augmented reality (AR)/ virtual reality (VR) applications. To list, 5G wireless technology, the Internet-of-Medical-Things (IoMT), artificial intelligence (AI), VR/AR tools and blockchain system are the five interconnected keys influencing digital healthcare. In summary, 5G transform current tedious manual processes into smartly automated workflows and provides integrated, enhanced patient care.
Esta historia es de la edición November 2020 de BioSpectrum Asia.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE BioSpectrum Asia
BioSpectrum Asia
Repligen introduces next-generation chromatography resins
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India
Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh
\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.
1 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Cartherics names Dr lan Nisbet as CEO
Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Neurophet ropes in Josh Cohen as Head of Americas Business
South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
India's Final Mile to TB Elimination
As the target year 2025 draws to a close, the Government of India has intensified and consolidated nationwide efforts to eliminate tuberculosis (TB) through the TB-Mukt Bharat Abhiyaan, implemented under the National Tuberculosis Elimination Programme (NTEP). India's decision to advance the TB elimination timeline ahead of global targets has driven sustained reforms across detection, treatment, prevention, nutrition support, and community engagement.
2 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Korea builds AI-engineered nasal spray antiviral platform
A research team at Korea Advanced Institute of Science and Technology has successfully developed a nasal (intranasal) antiviral platform using artificial intelligence (AI) technology to overcome the existing limitations of interferonlambda treatments, namely, being weak against heat and disappearing quickly from the nasal mucosa.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
"Industry needs to evolve and invest in ADC payloads with more differentiated mechanisms of action
Antibody drug conjugates (ADCs) are becoming highly valuable in the market, with currently 15 approved ADCs targeting 16 different indications for haematological and solid tumour malignancies. With key components of ADCs, such as mAbs, linkers, payloads, and conjugation technologies, undergoing rapid advancements, a solid foundation has been laid for future research and development in this field, particularly in North America which is the largest market shareholder for ADCs. US recently wrapped up the world's largest & definitive Antibody-Drug Conjugate event, World ADC, held in November 2025, highlighting the development of novel ADCs through key market players, and a surge in patent application filing for ADCs. Dr Allan Jordan, Vice President of Oncology Drug Discovery at Sygnature Discovery, UK spoke in detail with BioSpectrum Asia about the future outlook of ADCs.
4 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Cytiva and Fida Biosystems collaborate to improve molecular insight for faster drug discovery
Cytiva, a Danaher company and leader in the life sciences industry, and Fida Biosystems, a Danish company specialising in molecular analysis, have joined forces to expand analytical capabilities for protein research.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
BioSpectrum Excellence Awards Highlight Strength and Future of India's Biotechnology Sector
Former Secretary, Department of Biotechnology (DBT), Government of India, Dr Renu Swarup, underscored the importance of recognising excellence across the biotechnology ecosystem while chairing the jury at the BioSpectrum Excellence Awards.
1 min
BioSpectrum Asia Jan 2026
Translate
Change font size
